Gut Microbiome in Breast Cancer Patients May Help Prevent Heart Damage from Cancer Treatments
New research suggests that gut microbiome composition in breast cancer patients may help prevent chemotherapy-induced heart damage, opening avenues for probiotics-based protective strategies.
Recent research indicates that the composition of the gut microbiome in breast cancer patients might play a crucial role in protecting against heart damage, known as cardiotoxicity, caused by cancer therapies. The study involved 98 women over 60 from various European treatment centers, including Cyprus, Greece, and Italy. These women underwent echocardiograms to assess heart function and blood tests to identify biomarkers linked to higher risk of heart injury during treatment. Additionally, scientists performed genetic sequencing of gut bacteria to analyze their profiles before chemotherapy.
The findings revealed specific gut bacteria, particularly within the Bacteroidaceae family, were associated with biomarkers indicating increased vulnerability to heart damage. These bacteria's presence was similar to profiles observed in patients with heart failure, suggesting a potential link between gut flora and heart health during cancer treatment.
Dr. Athos Antoniades, leading the research, emphasized the significance of these findings, noting that certain bacteria in the gut might influence cardiac biomarkers and thus, the risk of heart damage. The study suggests a future where personalized probiotics could be developed to mitigate long-term cardiovascular side effects in cancer survivors.
The women involved in the study underwent detailed heart scans and blood tests, with genetic analysis revealing that an imbalance or overgrowth of certain bacteria, like Bacteroides, might contribute to inflammation and overall heart risk. This project, part of the broader CARDIOCARE initiative, aims to analyze 600 women to confirm these findings and explore probiotic interventions for heart protection.
The research was presented at the European Cardio-Oncology 2025 conference by the European Society of Cardiology. Ultimately, this work points to the promising potential of microbiome-targeted therapies to prevent or reduce heart-related complications in cancer patients, improving long-term health outcomes.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Genetic Mutation in Ashkenazi Jewish Men May Increase Prostate Cancer Risk, New Research Finds
A recent study uncovers a specific genetic mutation in Ashkenazi Jewish men linked to a significantly increased risk of prostate cancer, opening new opportunities for personalized screening and treatment.
Pediatricians' Group Recommends COVID-19 Vaccines for Young Children, Diverging from CDC Guidelines
The American Academy of Pediatrics has issued new COVID-19 vaccine recommendations for children, diverging from CDC guidance. The new guidelines advocate for broader vaccination coverage, especially for high-risk kids, amid rising cases and policy shifts, emphasizing individual choice and updated safety data.
Apitegromab Shows Promise in Enhancing Motor Function in Spinal Muscular Atrophy Patients
New clinical trial results reveal that apitegromab significantly enhances motor function in patients with nonambulatory spinal muscular atrophy, offering hope for better treatment options.
Innovative PET Tracer Allows Same-Day Imaging for Triple-Negative Breast and Urothelial Cancers
A new PET tracer enables rapid, same-day imaging of nectin-4 in aggressive breast and bladder cancers, helping improve diagnosis and personalized treatment.